Inhibiting lncRNA NEAT1 Increases Glioblastoma Response to TMZ by Reducing Connexin 43 Expression

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Glioblastoma multiforme (GBM) is an aggressive brain tumor.
• GBM exhibits resistance to standard chemotherapy, such as temozolomide (TMZ).
• Long non-coding RNAs (lncRNAs) are increasingly recognized for their roles in cancer development.

Purpose of the Study:

• To investigate the role of lncRNA NEAT1 in glioblastoma multiforme (GBM) progression.
• To elucidate the molecular mechanisms by which NEAT1 influences GBM response to temozolomide (TMZ).

Main Methods:

• Quantitative real-time PCR (qRT-PCR) to measure NEAT1 expression.
• RNA interference, cell proliferation, and apoptosis assays to assess NEAT1 function.
• Bioinformatics, luciferase reporter assays, and RNA immunoprecipitation (RIP) to identify molecular interactions.

Main Results:

• Elevated NEAT1 expression in recurrent gliomas compared to primary gliomas.
• NEAT1 acts as a competing endogenous RNA (ceRNA) for miR-454-3p, targeting Connexin 43 (Cx43).
• NEAT1 downregulation enhances GBM cell sensitivity to TMZ and improves mouse survival.

Conclusions:

• The NEAT1/miR-454-3p/Connexin 43 pathway is crucial for GBM cell response to TMZ.
• Targeting NEAT1 presents a potential therapeutic strategy for GBM treatment.